Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

L'examen de l'innocuité et de l'efficacité du garetosmab par rapport au placebo administré par voie intraveineuse (IV) chez les participants adultes atteints de fibrodysplasie ossifiante progressive (FOP) (OPTIMA)

26 octobre 2026 mis à jour par: Regeneron Pharmaceuticals

Étude de phase 3 randomisée et contrôlée par placebo pour évaluer l'innocuité, la tolérabilité et l'efficacité du garétosmab chez les patients atteints de fibrodysplasie ossifiante progressive

This study is researching an experimental drug called garetosmab. The study is focused on adult patients with fibrodysplasia ossificans progressiva (FOP).

The aim of the study is to see how safe and effective the study drug is in patients with FOP.

The study is looking at several other research questions, including:

  • What side effects may happen from receiving the study drug
  • How much study drug is in the blood at different times
  • Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects)

Aperçu de l'étude

Statut

Actif, ne recrute pas

Type d'étude

Interventionnel

Inscription (Réel)

63

Phase

  • Phase 3

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

    • Cape Town
      • Rondebosch, Cape Town, Afrique du Sud, 7700
        • University of Cape Town
    • New South Wales
      • St Leonards, New South Wales, Australie, 2065
        • Royal North Shore Hospital
      • São Paulo, Brésil, 05652-900
        • Hospital Israelita Albert Einstein
    • Biobio
      • Concepción, Biobio, Chili, 4030000
        • Universidad de Concepcion
      • Shanghai, Chine, 200065
        • Tongji Hospital of Tongji University
    • Cundinamarca
      • Chía, Cundinamarca, Colombie, 140013
        • Clinica Universidad de La Sabana
      • Seoul, Corée du Sud, 03080
        • Seoul National University Hospital
      • Madrid, Espagne, 28034
        • Hospital Universitario Ramon y Cajal
    • Stenbäckinkatu 11
      • Helsinki, Stenbäckinkatu 11, Finlande, 00029
        • HUS Children and Adolescents Park Hospital Clinical Trial Unit
      • Montpellier, France, 34090
        • Hôpital Lapeyronie
      • Paris, France, 75010
        • Hopital Lariboisiere
      • Hong Kong, Hong Kong, 22553838
        • Queen Mary Hospital
      • Genoa, Italie, 16147
        • IRCCS Istituto Giannina Gaslini
      • Fukuoka, Japon, 812-8582
        • Kyushu University Hospital
    • Aichi-ken
      • Nagoya, Aichi-ken, Japon, 466-8560
        • Nagoya University Hospital
    • Oita Prefecture
      • Yufu, Oita Prefecture, Japon, 879-5593
        • Oita University Hospital
      • Kuala Lumpur, Malaisie, 50586
        • Hospital Kuala Lampur
    • North Holland
      • Amsterdam, North Holland, Pays-Bas, 1081 HV
        • Amsterdam University Medical Center
    • Podkarpackie Voivodeship
      • Rzeszów, Podkarpackie Voivodeship, Pologne, 35-326
        • Szpital Centrum Medyczne Medyk
    • Greater London
      • Middlesex, Greater London, Royaume-Uni, HA7 4LP
        • Royal National Orthropaedic Hospital NHS Trust
    • California
      • Los Angeles, California, États-Unis, 90095
        • University of California Los Angeles (UCLA) Medical Center
    • Tennessee
      • Nashville, Tennessee, États-Unis, 37232
        • Vanderbilt University Medical Center

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Key Inclusion Criteria:

  1. Clinical diagnosis of Fibrodysplasia Ossificans Progressiva (FOP) [(based on findings of congenital malformation of the great toes, episodic soft tissue swelling, and/or progressive Heterotopic Ossification (HO)]
  2. Confirmation of FOP diagnosis with documentation of Type I activin A receptor (ACVR1) FOP causing mutation
  3. FOP disease activity within 1 year of screening visit. FOP disease activity is defined as pain, swelling, stiffness, or other signs and symptoms associated with FOP flare-ups; or worsening of joint function, or radiographic progression of HO lesions (increase in size or number of HO lesions) with/without being associated with flare-up episodes
  4. Willing and able to undergo CT imaging procedures and other procedures as defined in the protocol

Key Exclusion Criteria:

  1. Cumulative Analog Joint Involvement Scale (CAJIS) score at screening >19

  2. Participant has significant concomitant illness or history of significant illness such as but not limited to cardiac, renal, rheumatologic, neurologic, psychiatric, endocrine, metabolic, or lymphatic disease, that in the opinion of the study investigator might confound the results of the study or pose additional risk to the patient by their participation in the study

  3. Previous history or diagnosis of cancer

  4. Severely impaired renal function defined as estimated glomerular filtration rate <30 milliliter per minute (mL/min) (/1.73 m^2 calculated by the Modification of Diet in Renal Disease equation

  5. Uncontrolled diabetes defined as hemoglobin A1C (HbA1c) >9% at screening

  6. History of poorly controlled hypertension, as defined by:

    1. Systolic blood pressure ≥180 mm Hg or diastolic blood pressure ≥110 mm Hg at the screening visit
    2. Systolic blood pressure of 160 mm Hg to 179 mm Hg or diastolic blood pressure of 100 mm Hg to 10^9 mm Hg at the screening visit, AND a history of end-organ damage (including history of left-ventricular hypertrophy, heart failure, angina, myocardial infarction, stroke, transient ischemic attack, peripheral arterial disease, end-stage renal disease, and moderate-to-advanced retinopathy
  7. Known history of cerebral vascular malformation

  8. Cardiovascular conditions such as New York Heart Association class III or IV heart failure, cardiomyopathy, intermittent claudication, myocardial infarction, or acute coronary syndrome within 6 months prior to screening; symptomatic ventricular cardiac arrhythmia

  9. History of severe respiratory compromise requiring oxygen, respiratory support (eg, bilevel positive airway pressure [biPAP] or continuous positive airway pressure [CPAP]), or a history of aspiration pneumonia requiring hospitalization

  10. Prior use in the past year and concomitant use of bisphosphonates

  11. Concurrent participation in another interventional clinical study or a non-interventional study with radiographic measures or invasive procedures (eg, collection of blood or tissue samples)

  12. Treatment with another investigational drug, denosumab, imatinib or isotretinoin in the last 30 days or within 5 half-lives of the investigational drug, whichever is longer

  13. Pregnant or breastfeeding women

  14. Women of childbearing potential (WOCBP) who are unwilling to practice highly effective contraception, as defined in the protocol

  15. Male patients with WOCBP partners who are not willing to use condoms with WOCBP partners to prevent potential fetal exposure, as defined in the protocol

Note: Other protocol defined Inclusion/Exclusion Criteria apply

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Quadruple

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: High dose Garetosmab

Garetosmab is administered by intravenous (IV) administration every 4 weeks (Q4W)

Garetosmab is supplied as a liquid drug product and will be administered IV.

Autres noms:
  • REGN2477
  • PASATRU™
Expérimental: Low dose Garetosmab

Garetosmab is administered by IV administration Q4W

Garetosmab is supplied as a liquid drug product and will be administered IV.

Autres noms:
  • REGN2477
  • PASATRU™
Expérimental: Placebo

Placebo to match garetosmab, is supplied as a liquid solution without the monoclonal antibody (or the protein) and is administered IV Q4W.

Placebo to match garetosmab, is supplied as a liquid solution without the monoclonal antibody (or the protein) and is administered IV.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Number of New Heterotopic Ossification (HO) Lesions
Délai: Week 56

The HO is the abnormal growth of bone in non-skeletal tissues. New HO lesions were defined as HO lesions detectable by computed tomography (CT) that developed after baseline.

This endpoint represents the cumulative number of New HO Lesions across all participants.

Week 56
Number of Participants With Treatment-emergent (TE) Adverse Events of Special Interest (AESIs)
Délai: Baseline up to Week 56 [to include participants who discontinued earlier]

The following were considered AESIs:

  • Epididymitis, orchitis, hydrocele, scrotum pain and/or scrotum swelling
  • Moderate-to-severe episodes of spontaneous non-traumatic bleeding
  • Moderate epistaxis
  • Severe epistaxis
  • Skin infection/abscess that requires referral to specialist for treatment
Baseline up to Week 56 [to include participants who discontinued earlier]

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Number of Clinician-assessed Flare-ups
Délai: Baseline through Weeks 28 and 56

Investigator assessed flare-up events according to his/her medical judgment. A FOP flare-up was characterized as episodic, painful inflammatory soft tissue swelling.

This endpoint represents the cumulative number of Clinician-assessed Flare-ups across all participants.

Baseline through Weeks 28 and 56
Number of Participants With New HO Lesions at Weeks 28 and 56
Délai: Weeks 28 and 56

Reported as Yes/No

The HO is the abnormal growth of bone in non-skeletal tissues. New HO lesions were defined as HO lesions detectable by CT that developed after baseline.

Weeks 28 and 56
Total Volume of New HO Lesions
Délai: Weeks 28 and 56

The HO is the abnormal growth of bone in non-skeletal tissues. New HO lesions were defined as HO lesions detectable by CT that developed after baseline.

Weeks 28 and 56
Percentage of Participants With Participant-reported Flare-ups
Délai: Baseline through Weeks 28 and 56

Reported as Yes/No

Baseline through Weeks 28 and 56
Number of New HO Lesions
Délai: Week 28

The HO is the abnormal growth of bone in non-skeletal tissues. New HO lesions were defined as HO lesions detectable by CT that developed after baseline.

Week 28
Percentage of Participants With Clinician-assessed Flare-ups
Délai: Baseline through Weeks 28 and 56

Reported as Yes/No

Baseline through Weeks 28 and 56
Number of Participant-reported Flare-ups
Délai: Baseline through Weeks 28 and 56

Flare-up is defined as two or more of the following: pain, swelling, joint stiffness, or decrease in movement. The FOP flare-up dairy is a questionnaire and is self-completed by the participant daily.

This endpoint represents the cumulative number of Participant-reported Flare-ups across all participants.

Baseline through Weeks 28 and 56
Change From Baseline in Joint Function Assessment by Physician Using Cumulative Analog Joint Involvement Scale (CAJIS)
Délai: Baseline, Weeks 28 and 56

CAJIS is a clinician assessment of 15 major joints; each major joint rated normal unaffected (0), affected (1), or completely functionally ankylosed (2). The total score ranges from 0 to 30

Baseline, Weeks 28 and 56
Change in Pulmonary Function (Forced Expiratory Volume in 1 Second [FEV1]) as Assessed by Spirometry
Délai: Baseline, Weeks 28 and 56

Forced expiratory volume in 1 second (FEV1) will be determined by spirometry.

Baseline, Weeks 28 and 56
Change From Baseline in Disease Severity as Assessed by the Patient Global Impression of Severity (PGIS)
Délai: Baseline, Weeks 28 and 56

PGIS is a single item, self-administered questionnaire to assess the participant's global impression of severity. PGIS scores range from 0 to 4 ([0]: none, [1]: mild, [2]: moderate, [3]: severe, [4]: very severe). LS mean and SE were calculated using ANCOVA model, which included treatment as fixed effect and the baseline value as continuous covariate

Baseline, Weeks 28 and 56
Patient's Global Impression of Change (PGIC) Scale Score
Délai: Weeks 28 and 56

PGIC is a single item, self-administered questionnaire to assess the patient's global impression of change. The PGIC scale uses a 7-point rating format where participants select the response that best describes how their condition has changed: 1 = Very much improved, 2 = Much improved; 3 = Minimally improved; 4 = No change; 5 = Minimally worse; 6 = Much worse; 7 = Very much worse. LS mean and SE were calculated using ANCOVA model, which included treatment as fixed effect.

Weeks 28 and 56
Clinician's Global Impression of Change (CGIC) Scale Score
Délai: At Weeks 28 and 56

CGIC is a single-item questionnaire to assess the clinician's global impression of change. The clinician assessed the participant's condition and scored the change using the following standard 7-point scale: 1 = Very much improved, 2 = Much improved; 3 = Minimally improved; 4 = No change; 5 = Minimally worse; 6 = Much worse; 7 = Very much worse. LS mean and SE were calculated using ANCOVA model, which included treatment as fixed effect.

At Weeks 28 and 56
Concentration of Total Activin A in Serum Over Time
Délai: Day 1 (Week 0) predose and 30 minutes after the end of infusion (nominal Week 0.003), and Weeks 1, 4, 8, 12, 16, 20, 28, 36, 40, 44, 48, 52 and 56

Concentrations below the lower limit of quantitation (LLOQ) (0.000313 milligrams [mg]/L) were set to 0.

Day 1 (Week 0) predose and 30 minutes after the end of infusion (nominal Week 0.003), and Weeks 1, 4, 8, 12, 16, 20, 28, 36, 40, 44, 48, 52 and 56
Concentration of Garetosmab in Serum Over Time
Délai: Day 1 (Week 0) predose and 30 minutes after the end of infusion (nominal Week 0.003), and Weeks 1, 4, 8, 12, 16, 20, 28, 36, 40, 44, 48, 52 and 56

Concentrations below the LLOQ (0.078 mg/L) were set to 0.

Day 1 (Week 0) predose and 30 minutes after the end of infusion (nominal Week 0.003), and Weeks 1, 4, 8, 12, 16, 20, 28, 36, 40, 44, 48, 52 and 56
Number of Participants With Anti-drug Antibodies (ADA) to Garetosmab Over Time
Délai: Baseline through Week 56
Baseline through Week 56
Number of Participants With Titer Values of ADA to Garetosmab Over Time Through Week 56
Délai: Baseline through Week 56
Baseline through Week 56
Number of Clinician-assessed Flare-ups at Week 84
Délai: Through Week 84

Investigator assessed flare-up events according to his/her medical judgment. A FOP flare-up was characterized as episodic, painful inflammatory soft tissue swelling.

Week 84 Only for Patients on Extended Treatment

Through Week 84
Percentage of Participants With New HO Lesions at Week 84
Délai: At Week 84

Reported as Yes/No

Week 84 Only for Patients on Extended Treatment

At Week 84
Total Volume of New HO Lesions
Délai: At Week 84

Week 84 Only for Patients on Extended Treatment

At Week 84
Number of New HO Lesions
Délai: At week 84

Week 84 Only for Participants on Extended Treatment

At week 84
Percentage of Participants With Clinician-assessed Flare-ups
Délai: Through Week 84

Reported as Yes/No

Week 84 Only for Participants on Extended Treatment

Through Week 84
Change in Pulmonary Function (Forced Vital Capacity (FVC)) as Assessed by Spirometry
Délai: Baseline, Weeks 28 and 56

FVC will be determined by spirometry.

Baseline, Weeks 28 and 56
Change in Pulmonary Function (FEV1/FVC) as Assessed by Spirometry
Délai: Baseline, Weeks 28 and 56

The ratio of FEV1/FVC will be determined by spirometry.

Baseline, Weeks 28 and 56

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Les enquêteurs

  • Directeur d'études: Clinical Trial Management, Regeneron Pharmaceuticals

Publications et liens utiles

La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

21 novembre 2022

Achèvement primaire (Réel)

17 juillet 2025

Achèvement de l'étude (Estimé)

27 février 2029

Dates d'inscription aux études

Première soumission

4 mai 2022

Première soumission répondant aux critères de contrôle qualité

23 mai 2022

Première publication (Réel)

27 mai 2022

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

17 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

26 octobre 2026

Dernière vérification

1 octobre 2026

Plus d'information

Termes liés à cette étude

Autres numéros d'identification d'étude

  • R2477-FOP-2175
  • 2022-000880-40 (Identificateur de registre: EudraCT)
  • 2023-508350-26-00 (Identificateur de registre: CTIS (EU))
  • 2023 (Subvention/contrat des NIH des États-Unis)

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

OUI

Description du régime IPD

All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing

Délai de partage IPD

When Regeneron has:

  • received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development
  • made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry)
  • the legal authority to share the data, and
  • ensured the ability to protect participant privacy

Critères d'accès au partage IPD

Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf

Type d'informations de prise en charge du partage d'IPD

  • PROTOCOLE D'ÉTUDE
  • SÈVE
  • CIF
  • ANALYTIC_CODE
  • RSE

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Oui

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner